Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331390

Institution ID

3331390

Institution full name and acronym

UCB Biosciences

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

A 12-MONTH NONINTERVENTIONAL OBSERVATIONAL MULTINATIONAL STUDY TO EVALUATE EFFECTIVENESS, TOLERABILITY, AND QUALITY OF LIFE OF BRIVARACETAM ADJUNCTIVE THERAPY IN EARLIER TREATMENT LINES IN ADULT PATIENTS WITH HISTORY OF PARTIAL-ONSET SEIZURES IN DAILY CLINICAL PRACTICE (BRITOBA)
A European Study of the Effectiveness of Risk Minimisation Measures for Fenfluramine in Dravet Syndrome (TAPESTRY eRMM)
A multicenter postmarketing study to evaluate the placental transfer of certolizumab pegol in pregnant women receiving treatment with Cimzia® (certolizumab pegol) (CRIB)
A MULTICENTER, OBSERVATIONAL POST-MARKET CLINICAL FOLLOW-UP STUDY IN PATIENTS WITH RA, PsA, OR axSpA ASSESSING THE PATIENT EXPERIENCE WITH THE CIMZIA AVA DEVICE OR OTHER TNF-BLOCKER AUTO-INJECTOR DEVICES
A multicenter, postmarketing study to evaluate the concentration of certolizumab pegol in the breast milk of mothers receiving treatment with Cimzia® (certolizumab pegol) (CRADLE)
A Registry of Patients Treated with Fintepla (TAPESTRY Registry)
An observational follow-up study of women who become pregnant while participating in a certolizumab pegol (CZP) clinical study or whose pregnancies have otherwise been reported to UCB due to potential CZP exposure during pregnancy
An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B
Comparing the incidence of acute renal failure in patients with epilepsy exposed to levetiracetam versus other antiepileptic drugs
EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU ADR ALLIANCE
EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO ADHERENCE TO THE RISK MINIMIZATION MEASURES FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE
European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance
EVALUATING THE OCCURRENCE OF ADVERSE EVENTS AMONG PEDIATRIC PATIENTS EXPOSED TO INTRAVENOUS LACOSAMIDE (VIMPAT®) USING REAL WORLD DATA
VALIDATION STUDY PROTOCOL (OP0007) FOR THE EUROPEAN NON-INTERVENTIONAL POST- AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS CARDIOVASCULAR EVENTS OF MYOCARDIAL INFARCTION AND STROKE AND ALL-CAUSE MORTALITY FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0004) AND EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0006)
XYREM EU-RMP: Effectiveness Assessment Protocol of Educational Materials